252061-94-2

Usage

Uses

Used in Pharmaceutical Industry:
7-(benzyloxy)-1,2,3,4-tetrahydroisoquinoline is used as a potential drug candidate for the development of new medications for various medical conditions. Its antioxidant and antifungal properties make it a valuable target for research and therapeutic applications.
Used in Antioxidant Applications:
7-(benzyloxy)-1,2,3,4-tetrahydroisoquinoline is used as an antioxidant agent, which can help protect cells from oxidative damage and potentially reduce the risk of various diseases associated with oxidative stress.
Used in Antifungal Applications:
7-(benzyloxy)-1,2,3,4-tetrahydroisoquinoline is used as an antifungal agent, exhibiting activity against various fungal pathogens, making it a potential candidate for the development of new antifungal drugs to combat fungal infections.

Upstream product

• 50-00-0 formaldehyd 
• 51179-05-6 2-(4-(benzyloxy)phenyl)ethanamine 
• 591-31-1 3-methoxy-benzaldehyde 
• 3179-09-7 1-methoxy-3-(2-nitrovinyl)benzene 
• 2039-67-0 2-(3-methoxyphenyl)-1-ethanamine 
• 57196-62-0 6-methoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride 
• 942150-85-8 bis(6-methoxy-N-1,2,3,4-tetrahydroisoquinolinyl)methane 
• 59839-23-5 6-hydroxy-1,2,3,4-tetrahydroisoquinoline hydrobromide 
• 158984-83-9 N-tert-butoxycarbonyl-6-hydroxy-1,2,3,4-tetrahydroisoquinoline 
• 164148-88-3 6-benzyloxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 
• 100-39-0 benzyl bromide 

Downstream Products

• 164148-85-0 (6-benzyloxy-3,4-dihydro-1H-isoquinolin-2-yl)-acetic acid tert-butyl ester 
• 1429253-97-3 C₂₈H₂₆N₄O₂ 
• 94086-31-4 6-hydroxy-2-(3,4,5-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinoline 
• 1623785-66-9 6-sulfamoyloxy-2-(3,4,5-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinoline 
• 1623785-65-8 6-benzyloxy-2-(3,4,5-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinoline 
• 1064200-16-3 2-(3,5-dimethoxybenzoyl)-6-O-sulfamoyl-1,2,3,4-tetrahydroisoquinoline 
• 1064200-01-6 2-(3,5-dimethoxybenzoyl)-6-hydroxy-1,2,3,4-tetrahydroisoquinoline 
• 1064199-80-9 6-benzyloxy-2-(3,5-dimethoxybenzoyl)-1,2,3,4-tetrahydroisoquinoline 
• 1064197-69-8 6-benzyloxy-2-(3-methoxybenzyl)-1,2,3,4-tetrahydroisoquinoline 
• 189572-92-7 {6-[4-(tert-butoxycarbonylamino-imino-methyl)-benzyloxy]-3,4-dihydro-1H-isoquinolin-2-yl}-acetic acid tert-butyl ester 
• 164148-90-7 [6-(4-cyano-benzyloxy)-3,4-dihydro-1H-isoquinolin-2-yl]-acetic acid tert-butyl ester 

Relevant academic research and scientific papers

Compounds and methods of use

Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X1, X2, X3, X4, Y, A, L1, L2, R1, R2, R5, m and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

CuII/TEMPO-Catalyzed Enantioselective C(sp3)–H Alkynylation of Tertiary Cyclic Amines through Shono-Type Oxidation

A novel strategy for asymmetric Shono-type oxidative cross-coupling has been developed by merging copper catalysis and electrochemistry, affording C1-alkynylated tetrahydroisoquinolines with good to excellent enantioselectivity. The use of TEMPO as a co-catalytic redox mediator is crucial not only for oxidizing a tetrahydroisoquinoline to an iminium ion species but also for decreasing the oxidation potential of the reaction. A novel bisoxazoline ligand is also reported.

Design and Synthesis of Potent, Selective Inhibitors of Protein Arginine Methyltransferase 4 against Acute Myeloid Leukemia

PRMT4 is a type I protein arginine methyltransferase and plays important roles in various cellular processes. Overexpression of PRMT4 has been found to be involved in several types of cancers. Selective and in vivo effective PRMT4 inhibitors are needed for demonstrating PRMT4 as a promising therapeutic target. On the basis of compound 6, a weak dual PRMT4/6 inhibitor, we constructed a tetrahydroisoquinoline scaffold through a cut-and-sew scaffold hopping strategy. The subsequent SAR optimization efforts employed structure-based approach led to the identification of a novel PRMT4 inhibitor 49. Compound 49 exhibited prominently high potency and selectivity, moderate pharmacokinetic profiles, and good antitumor efficacy in acute myeloid leukemia xenograft model via oral administration, thus demonstrating this compound as a useful pharmacological tool for further target validation and drug development in cancer therapy.

SAR based design of nicotinamides as a novel class of androgen receptor antagonists for prostate cancer

Molecular knowledge of pure antagonism and systematic SAR study offered a direction for structural optimization of DIMN to provide nicotinamides as a novel series of AR antagonists. Nicotinamides with extended linear scaffold bearing sterically bulky alkoxy groups on isoquinoline end were synthesized for H12 displacement. AR binding affinity and molecular basis of antiandrogenic effect establish the optimized derivatives, 7au and 7bb, as promising candidates of second generation AR antagonists for advanced prostate cancer.

S1P RECEPTORS MODULATORS

The invention relates to novel compounds that have S1P receptor modulating activity and, preferably, apoptotic activity and/or anti proliferative activity against cancer cells and other cell types. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, cancer. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as cancer.